Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.
International cervical cancer experts agreed on 16 evidence-based guidelines for trial design and care, highlighting urgent needs for molecular testing standardization in low-resource settings.
The inaugural GCIG Cervical Cancer Consensus Conference (Dublin, 2024) produced 16 consensus statements on clinical trial design for cervical cancer, covering diagnosis, staging, and management across all disease stages, with unanimous adoption by 33 GCIG member groups. Areas of persistent unmet need were tabulated, including standardization of molecular biomarkers, inclusion criteria for locally advanced disease, and trial infrastructure for LMICs where cervical cancer burden is disproportionately high.
What the study was
- Study design
- international_consensus_guideline
- Population
- Cervical cancer patients across all disease stages; 33 GCIG member groups globally
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Lancet Oncol
Why it surfaced
Inaugural international consensus (Lancet Oncol) from 33 GCIG groups shaping the design architecture of future cervical cancer clinical trials globally—directly impacts how research priorities, eligibility criteria, and endpoints will be harmonized for the disease with the 4th highest cancer mortality in women worldwide.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.